Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design
Pfeffer M, McMurray J, Leizorovicz A, Maggioni A, Rouleau J, Van de Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers M, Velazquez E, Califf R, Investigators* F. Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design. American Heart Journal 2000, 140: 727-750. PMID: 11054617, DOI: 10.1067/mhj.2000.108832.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin IIAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCaptoprilCause of DeathDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationHumansMulticenter Studies as TopicMyocardial InfarctionOdds RatioPatient SelectionProportional Hazards ModelsRandomized Controlled Trials as TopicResearch DesignSample SizeTetrazolesValineValsartanConceptsAngiotensin II receptor blockersII receptor blockersAcute myocardial infarctionMyocardial infarctionReceptor blockersVentricular dysfunctionHeart failureAngiotensin II receptor blocker valsartanEnzyme inhibitorsMajor nonfatal cardiovascular eventsAcute Myocardial Infarction trialAngiotensin-converting enzyme inhibitorDose of captoprilMultiple practice patternsNonfatal cardiovascular eventsUse of valsartanMyocardial Infarction trialReceptor blocker valsartanHigh-risk patientsLeft ventricular dysfunctionParallel-group studyRenin-angiotensin systemManagement of patientsCombination of captoprilLong-term treatment